It is beyond the scope of this study to report data for the focused set of nearly 400 other genes included in the transcriptome panel, however evaluating RNA for immune gene expression in addition to PD-L1 has been shown to be predictive of efficacy to anti-PD-1 therapy across multiple tumor types with more accuracy than PD-L1 IHC [35–37]. The gene discussed is CD274; the disease is neoplasm.